Valneva Shares Face Investor Uncertainty After Revised Outlook

Financial Recalibration and Capital Reinforcement

Investors in Valneva are navigating turbulent waters as the biotechnology firm delivers a dual announcement: significantly reduced annual projections coupled with an unexpected capital infusion. This conflicting news creates a complex landscape for shareholders weighing the company’s future trajectory against immediate financial pressures.

Valneva has substantially revised its full-year guidance across multiple operational segments. The company now anticipates:

• Total Revenue: €165 to €180 million (down from previous €180-190 million projection)
• Product Revenue: €155 to €170 million
• R&D Expenditure: €80 to €90 million (reduced from €90-100 million range)